Detailed Information on Publication Record
2020
Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection
GABŁO, Natalia Anna, Karolína TRACHTOVÁ, Vladimír PROCHÁZKA, Jan HLAVSA, Tomáš GROLICH et. al.Basic information
Original name
Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection
Authors
GABŁO, Natalia Anna (616 Poland, belonging to the institution), Karolína TRACHTOVÁ (203 Czech Republic, belonging to the institution), Vladimír PROCHÁZKA (203 Czech Republic, belonging to the institution), Jan HLAVSA (203 Czech Republic, belonging to the institution), Tomáš GROLICH (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic), Josef SROVNAL (203 Czech Republic), Alona REHULKOVA (203 Czech Republic), Martin LOVECEK (203 Czech Republic), Pavel SKALICKY (203 Czech Republic), Ioana BERINDAN-NEAGOE (642 Romania), Zdeněk KALA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, belonging to the institution)
Edition
Journal of Clinical Medicine, BASEL, MDPI, 2020, 2077-0383
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30218 General and internal medicine
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.241
RIV identification code
RIV/00216224:14740/20:00118646
Organization unit
Central European Institute of Technology
UT WoS
000568145300001
Keywords in English
Pancreatic ductal adenocarcinoma; prognosis; microRNAs
Tags
International impact, Reviewed
Změněno: 3/3/2021 15:25, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive cancers with a less than 6% five-year survival rate. Circulating microRNAs (miRNAs) are emerging as a useful tool for non-invasive diagnosis and prognosis estimation in the various cancer types, including PDAC. Our study aimed to evaluate whether miRNAs in the pre-operative blood plasma specimen have the potential to predict the prognosis of PDAC patients. In total, 112 PDAC patients planned for surgical resection were enrolled in our prospective study. To identify prognostic miRNAs, we used small RNA sequencing in 24 plasma samples of PDAC patients with poor prognosis (overall survival (OS) < 16 months) and 24 plasma samples of PDAC patients with a good prognosis (OS > 20 months). qPCR validation of selected miRNA candidates was performed in the independent cohort of PDAC patients (n= 64). In the discovery phase of the study, we identified 44 miRNAs with significantly different levels in the plasma samples of the group of good and poor prognosis patients. Among these miRNAs, 23 showed lower levels, and 21 showed higher levels in plasma specimens from PDAC patients with poor prognosis. Eleven miRNAs were selected for the validation, but only miR-99a-5p and miR-365a-3p were confirmed to have significantly lower levels and miR-200c-3p higher levels in plasma samples of poor prognosis cases. Using the combination of these 3-miRNA levels, we were able to identify the patients with poor prognosis with sensitivity 85% and specificity 80% (Area Under the Curve = 0.890). Overall, 3-miRNA prognostic score associated with OS was identified in the pre-operative blood plasma samples of PDAC patients undergoing surgical resection. Following further independent validations, the detection of these miRNA may enable identification of PDAC patients who have no survival benefit from the surgical treatment, which is associated with the high morbidity rates.
Links
| NV16-31314A, research and development project |
|